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Background: An association between innate immunity including Toll-like receptors (TLRs) and COPD is reported
recently; TLR4 deficiency in lung can cause emphysema in animals, which is not evident in humans. We analyzed
the association of TLR4 expression, airflow limitation and emphysema in smokers.
Methods: We enrolled patients of ≥40years old with smoking histories of ≥10 pack-years and who had undergone
lung resection. We measured TLR4 expression in lung lysates. The severity of emphysema was evaluated on
computed tomography. TLR4 expression was also evaluated immunohistochemically.
Results: In total, 53 patients were enrolled. Forced expiratory volume in one second per forced vital capacity
(FEV1/FVC) increased (P=0.03) and emphysema score decreased (P=0.01) as TLR4 expression increased. These were
still significant, in multiple regression analysis including sex, age, tuberculosis history, smoking history and inhaled
corticosteroid (ICS) usage. We also classified patients as high, intermediate, and low expressers according to TLR4
expression. Although no differences in age, gender, tuberculosis, or smoking history were observed among the
groups, emphysema severity increased significantly (P = 0.02) and FEV1/FVC decreased significantly (P = 0.006) in
TLR4 low expresser. The difference in TLR4 expression based on immunohistochemistry was most prominent in
bronchial and alveolar epithelial cells.
Conclusion: Down-regulated TLR4 expression in lung was associated with emphysema and airflow limitation
in smokers.
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Chronic obstructive pulmonary disease (COPD) is a
major global health problem, with a prevalence of 5–25%
in adults [1]. COPD is projected to be the fourth leading
cause of death by 2020 [2,3]. Smoking is the most
important cause of COPD, accounting for 90% of the
cumulative risk [4]. Nevertheless, not all smokers will
develop COPD. In fact, only a small portion (about 15%)
will develop clinically relevant disease [5,6]. Compared* Correspondence: ctlee@snu.ac.kr
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reproduction in any medium, provided the orwith non-smokers, smokers have a steeper lung function
decline. However, this is only true of susceptible smokers,
as non-susceptible smokers can have the same lung func-
tion decline as never-smokers [7]. This implies that add-
itional pathogenesis is involved in airway limitation and
the development of emphysema.
Several candidate genes and biomarkers have been
suggested to explain “additional pathogenesis” in smokers
[8]. Candidate genes regulate proteases and antiproteases,
modulate the metabolism of toxic substances in cigarette
smoke, participate in mucocillary clearance, or influence
inflammatory mediators [9], but the only well-established
genetic risk factor is alpha-1-antitrypsin [10,11]. Microsat-
ellite DNA instability has been proposed as a useful genetic
screening marker for susceptible smokers [12]. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lee et al. Respiratory Research 2012, 13:106 Page 2 of 8
http://respiratory-research.com/content/13/1/106unlike other diseases, COPD lacks established markers that
can be applied to track disease progression [13].
Recently, some studies have reported an association
between innate immunity and COPD. The main compo-
nents of innate immunity are phagocytes of inflamma-
tory cells, which discriminate between pathogens and
self cells by utilizing signals from Toll-like receptors
(TLRs). TLRs may be important in COPD because they
participate in defense against viral and bacterial infec-
tions, and infections in the airway worsen the disease
process in the lungs of patients with COPD [14]. Among
the TLRs, TLR4 appears to play a pivotal role in lung
homeostasis by contributing to the defense of endothe-
lial cells against oxidants [15,16]. Moreover, TLR4 defi-
ciency in the lung leads to spontaneous emphysema in
animals, which is associated with an oxidant/antioxidant
imbalance [17]. Thus, difference in TLR4 expression has
been associated with COPD development in some ani-
mals, but this is not evident in humans.
In the present study, we hypothesized that TLR4
expression differs among people and that this can be
associated with the emphysema or airflow limitation. To
test this hypothesis, we analyzed the association between
emphysema severity, TLR4 expression in lung tissue and
emphysema.Material and methods
Study patients
We recruited all patients with smoking history ≥10
pack-years, who were ≥40 years old, and whose lung had
been resected for lung cancer from 2008 to 2010 at
Seoul National University Bundang Hospital. We en-
rolled the patients whose normal lung tissues were avail-
able from a certified tissue bank. The lung tissues were
dissected by pathologists to discriminate normal tissue
from cancer and then preserved at −70°C until the ex-
periment. The tissue was taken at peripheral area, at
least 3cm apart from the cancer. This study was
reviewed and approved by the Institutional Review
Board of Seoul National University Bundang Hospital
(B1008/110-006).
Western blot assay
TLR4 expression was assessed by Western blot analysis.
Normal lung tissues were homogenized (IKA T10 Basic;
Younjin Corp., Gunpo, Korea) in lysis buffer (cell signal-
ing, Denver, MA, USA) and 30ug protein was used for
each sample. Western blot analysis was performed with
anti-TLR4 antibody (H-80; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at a concentration of 0.2 μg/ml as
previously described [18]. The signal was detected and
quantified using Scion Image v7.0 (Scion Corp., Fred-
erick, MD, USA). All samples were normalized to actinsignals. The results were used to categorize patients
into three groups: high (TLR4/actin > 0.5), intermediate
(0.15 ≤ TLR4/actin < 0.5), and low expressers (TLR4/
actin < 0.15).
Radiological features and grading of emphysema severity
Computed tomography (CT) images of all enrolled sub-
jects were reviewed by an experienced chest radiologist
(T.J.K.) and a pulmonologist (S.W.L.) without patients’
information. After jointly scoring 10 patients, who were
not enrolled in this study, and adjusting their eye levels,
the two readers independently reviewed the images. Any
disagreements were discussed by the two readers, and
another experienced pulmonologist (C.T.L.) helped in
reaching an agreement. Preoperative CT images within 1
month before the resection were reviewed, and emphy-
sema severity was scored by the Goddard classification
[19]. Briefly, six CT images were selected for each pa-
tient: right and left fields of the upper lung (1 cm above
the superior margin of the aortic arch), of the middle
lung (1 cm below the carina), and of the lower lung
(3 cm above top of the diaphragm). We scored each
image from 0 to 3 according to the proportion of
vascular disruption and the areas of low attenuation.
A score of 0 meant no abnormality; 1, 0–25% involvement;
2, 25–50%; 3, 50–75%; and 4, 75–100% involvement. Em-
physema was graded based on the total score of the six
images: 0–7, mild; 8–15, moderate; and 16–18, severe
emphysema.
CT scanning was performed during full inspiration
using various CT scanners, including a Brilliance-64,
MX-8000 IDT, and iCT 256 (Philips Medical Systems,
Cleveland, OH, USA). Scanning was conducted from the
thoracic inlet to the upper portion of the kidneys.
Images were obtained using a window level of 600
Hounsfield units (HU), a window width of 1500 HU
(lung window), a level of 30 HU, and a width of 400 HU
(mediastinal window). Conventional CT images were
obtained from the thoracic inlet to the lung base using a
3-mm section thickness.
Pulmonary function test
All patients underwent a pulmonary function test within
1 month before resection. We used the results (without
bronchodilation) that contained the largest forced ex-
piratory volume in one second (FEV1). Spirometry was
conducted by trained pulmonary technicians, according
to the 2005 American Thoracic Society/European Re-
spiratory Society recommendations [20] using a Vmax229
spirometer (Sensor-Medics, Yorba Linda, CA, USA).
Exposure of rats to cigarette smoke
We performed animal experiments to exclude the possibil-
ity that smoking and acquired emphysema development
Figure 1 The results of a pilot study. Five smokers without
emphysema showed higher TLR4 expressions than five smokers
with emphysema. Each lane indicates TLR4 expression in lung of
one patient.
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causal relationship more clearly. Three eight-week-old
inbred female Lewis rats (Orient Bio, Seongnam, Korea)
were exposed to smoke as previously described [21].
Three control animals inhaled only clean room air. The
Institutional Animal Care and Use Committee of Asan
Medical Center approved this study.
Immunohistochemistry (IHC)
To analyze the major cells that resulted in a difference
in TLR4 expression, immunohistochemical staining for
TLR4 was performed in three randomly selected patients
with emphysema who were low TLR4 expressers and
three randomly selected patients without emphysema
who were high TLR4 expressers. For the IHC analysis,
4-μm-thick sections were cut from the patient’s lung tis-
sue blocks, deparaffinized in xylene, and rehydrated in a
graded alcohol series. Antigen retrieval was performed
in pH 6.0 citrate-phosphate buffer using a microwave
oven for 15 min. The sections were incubated with anti-
TLR4 antibody (1:50; Santa Cruz Biotechnology) for 1 h
at room temperature. To detect the signals, an Envision
kit (Dako, Glostrup, Denmark) was used according to
the manufacturer’s instruction. An experienced patholo-
gist (J.H.P.), who was blinded to the patient information,
read the IHC findings. TLR4 expression was graded
from 0 to 3 (0, no or very faint staining; 1, positive
staining; 2, strong positive staining; 3, very strong posi-
tive staining).
Statistical analysis
Emphysema severity and lung function according to
TLR4 expression were compared using linear regression
analysis. Comparison between groups was analyzed by
Spearman correlation for continuous variables and the
χ2 test for categorical variables. In the multivariate ana-
lysis, the backward selection method was used to ex-
clude multi-collinearity. Statistical significance was
assessed at a two-tailed P-value of 0.05. Agreements in
the emphysema scores between the two readers were
determined using the κ statistic [22]. All data are presented
as means ± standard deviations. All statistical analyses were




Fifty-three patients were enrolled. The median age was
67 years (range, 37–78 years), and 51 patients (96.2%)
were male. Mean smoking history was 31.3 ± 21.2 pack-
years. Thirty nine patients (73.6%) were current smokers
(smoking within 3 months before resection), and 11
(20.8%) patients had history of tuberculosis. Five patients
(9.4%) were using inhaled corticosteroid before resection.A pilot study showed that TLR4 expression was lower
in five patients with emphysema than in the other five
without emphysema (Figure 1). A total of 33 (62.3%)
patients were diagnosed with COPD by spirometry
(FEV1/FVC < 0.7) [23].
Emphysema severity and pulmonary function according
to TLR4 expression
FEV1/FVC increased (P=0.03) and emphysema score
decreased (P=0.01) as TLR4 expression increased (Figure 2).
These were still significant, in multiple regression ana-
lysis including sex, age, tuberculosis history, smoking
history and inhaled corticosteroid (ICS) usage within
3 months, which could affect pulmonary function and
emphysema development [24-26]; β of TLR4 expres-
sion = 0.11 (95% confidence interval [CI] 0.007–0.22)
for FEV1/FVC (P = 0.04) and −0.41 (95% CI =
−13.1– -3.00) for emphysema score (P = 0.002).
We categorized the patients into three groups accord-
ing to TLR4 expression as described above. Twelve
patients were low expressers, 25 patients were inter-
mediate expressers, and 16 patients were high expres-
sers. No differences in age, gender, tuberculosis, or
smoking history were observed among the groups
(Table 1). The mean emphysema score increased as
TLR4 expression decreased; the mean emphysema
scores of the high, intermediate, and low expressers were
3.63 ± 4.77, 4.92 ± 4.60, and 8.33 ± 5.26, respectively
(P = 0.02, Figure 3A). The TLR4 low expresser group
included a higher number of severe-stage emphysema
cases; the proportions of severe compared with mild
emphysema in the high, intermediate, and low expressers
were 43.8% (7/16), 72.0% (18/25), and 83.4% (10/12)
(P = 0.007, Figure 3B). Airflow limitation also became
severer with lower levels of TLR4 expression; the mean
FEV1 per forced vital capacity (FVC) values in the high,
intermediate, and low expressers were 0.69 ± 0.07, 0.67 ±
0.11, and 0.58 ± 0.11 (P = 0.006, Figure 3C). However,
there was no significant difference in patients with
COPD (8/16 [50.0%] in high, 15/25 [60.0%] in intermedi-
ate and 10/12 [82.3%] in low expressers, respectively,
Figure 2 Airflow limitation and emphysema severity according to TLR4 expression. (A) FEV1/FVC increased and (B) emphysema score
decreased as TLR4 expression increased. TLR4, Toll-like receptor 4; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.
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high, 93.2 ± 17.3 and 86.2 ± 11.0 in low expressers, re-
spectively, P=0.52) among groups. TLR4 expression was
higher in patients without COPD than with COPD (0.45 ±
0.26 and 0.33 ± 0.25), but it was not statistically significant
(P=0.11).
Agreement between the two readers (T.J.K. and S.W.L.)
for emphysema grades was almost perfect (κ = 0.82,
P < 0.001). The differences in emphysema scores between
the two readers were 0 for 30 (56.6%) patients, 1 for 12
(22.6%) patients, 2 for nine (17.0%) patients, and ≥3 for
two (3.8%) patients.Major cells resulting in TLR4 expression differences in
lung tissue
Immunohistochemical staining for TLR4 showed that
bronchial and alveolar epithelial cells were the major cells
exhibiting differences in TLR4 expression. Alveolar macro-
phages showed high TLR4 expression in all patients andTable 1 Comparison of characteristics and pulmonary functio
Characteristic Low Expressers Interm
(TLR4/actin < 0.15) (0.15
N = 12 N = 2
Age, years 65.3 ± 8.3 64.0 ±
Male gender, n (%) 12 (100) 24 (96
Smoking, pack-years 38.8 ± 27.2 35.6 ±
Current smoker, n (%) 10 (83.3) 20 (80
TB history present, n (%) 2 (16.7) 6 (24.0
ICS users*, n (%) 2 (16.7) 2 (8.0)
TLR4, toll-like receptor 4; TB, tuberculosis; ICS, inhaled corticosteroid; FEV1, forced e
obstructive pulmonary disease.
*The number of patients with inhaled corticosteroid prescribed within 3 months of
prescribed in four patients and fluticasone 500mcg with formoterol 50mcg twice athus did not contribute to the difference in expression
among groups (Figure 4).
TLR4 Expression among inbred rats according to acquired
emphysema development
We compared TLR4 expression between inbred rats
with and without emphysema to exclude the possibility
that acquired emphysema development itself caused by
smoking can affect TLR4 expression. We confirmed em-
physema development after 6 months of smoke expos-
ure. However, no difference in TLR4 expression was
observed between rats with and without emphysema
(Figure 5).
Discussion
We showed that a down-regulated TLR4 expression in
the lung can be a predictor or biomarker of emphysema
in smokers or biomarker of emphysema, as patients with
down-regulated TLR4 expression had a greater probabil-
ity of developing emphysema and airflow limitation.n between the groups
ediate Expressers High Expressers P-value
≤ TLR4/actin < 0.5) (TLR4/actin ≥ 0.5)
5 N = 16
9.2 67.4 ± 7.8 0.49
.0) 15 (93.8) 0.69
17.8 38.8 ± 22.3 0.87
.0) 9 (56.3) 0.17
) 3 (18.7) 0.85
1 (6.3) 0.61
xpiratory volume in one second; FVC, forced vital capacity; COPD, chronic
lung resection. Fluticasone 250mcg with formoterol 50mcg twice a day was
day in one low expresser.
Figure 3 Comparison of emphysema severity and pulmonary function between three groups according to TLR4 expression. (A) Mean
emphysema scores increased as TLR4 expression decreased. (B) Cases of severe emphysema were more common among patients with low TLR4
expression levels. (C) Airflow limitation was more severe at lower TLR4 expression levels. FEV1, Forced expiratory volume in one second; FVC,
Forced vital capacity.
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expression levels in bronchial and alveolar epithelial cells.
Smoke-induced emphysema itself did not appear to alter
TLR4 expression; therefore TLR4 expression seems to
affect emphysema development or progression, rather than
vice versa.Figure 4 Toll-like receptor 4 (TLR4) immunohistochemistry of lung tis
emphysema. Arrows indicate high TLR4 expressions in bronchial epithelium
Immunohistochemical staining shows that bronchial and alveolar epithelial
experienced pathologist (J.H.P.), who was blinded to the patient informatio
(0, no or very faint staining; 1, positive staining; 2, strong positive staining;Several studies have shown that defects in innate
TLR4-mediated immunity can be associated with em-
physema. TLR4 knockout causes spontaneous emphy-
sema in animals [17]. The presence of the TLR4-T339I
polymorphism is associated with a 2.4-fold increased risk
for developing COPD, highlighting the relationshipsues patients. (A) Tissues from high TLR4 expressers without
. (B) Tissues from low TLR4 expressers with emphysema.
cells exhibited major differences in TLR4 expression (×200). An
n, read the IHC findings. TLR4 expression was graded from 0 to 3
3, very strong positive staining).
Figure 5 Toll-like receptor 4 (TLR4) expressions in lung tissues of inbred rats with and without emphysema. (A) Lung tissue shows the
development of emphysema after 6 months of exposure to smoke. However, The IHC stain of TLR4 showed no difference in expression between
rats with and without emphysema (×40). (B) TLR4 expression in the lungs is not different between smoke-exposed and control rats in Western
blot analysis.
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ment [27]. The Gly299 allele is present at a decreased
frequency among patients with COPD and may be ab-
sent from COPD patients who have never smoked [28].
Our findings can make an important contribution on
the relationship between innate immunity and COPD,
because they show that down-regulated TLR4 expression
in the lung may be related to emphysema in humans, as
in animals.
An association between TLR4 expression and COPD
has also been noted previously. Most studies have sug-
gested that TLR4 expression is decreased in the blood of
patients with COPD. The peripheral blood TH1 cell re-
sponse to lipopolysaccharide (LPS) is impaired in
patients with COPD compared with the response in
never-smokers, and TLR4 overexpression via transfec-
tion restores this impairment [29]. Compared with less
severe disease, severe COPD is associated with reduced
TLR4 expression in the nasal epithelium [24]. In con-
trast to some positive results in blood, cells in a sputum
analysis failed to show this relationship. TLR4 expression
on sputum neutrophils was not different in COPD
patients [30], and TLR4 mRNA in induced sputum did
not differ significantly between COPD patients and
healthy controls [31]. A previous study showed no
significant difference in TLR4 expression in epithelial
cells between COPD and normal subjects, but several
factors such as smoking history, age and sex were not
controlled and small number subjects limited the
power of test [32]. This study is meaningful becausewe compare the TLR4 expression among smokers.
Previous studies compare the expression between
smoker COPD and never-smoker controls [25,33].
Theoretically, TLR4 deficiency may partially protect
against smoke-induced emphysema, because TLR4 defi-
ciency partially prevents smoke-induced influx of den-
dritic cells, lymphocytes, and neutrophils [16]. Clear
correlations have been found between the numbers of
these inflammatory cells and the severity of COPD
[34,35]. However, previous studies and our study have
shown that TLR4 deficiency does not protect against the
development of emphysema. To the contrary, it appears
to be related with emphysema development, which can
be explained by the role of TLR4 in the respiratory
system. In TLR4 deficient mouse, NADPH oxidase was
up-regulated in lungs, resulting in increased oxidant
generation and elastolytic activity [17]. Expression of the
autophagic protein LC3B and markers of cell death in
response to cigarette smoke exposure were increased in
epithelial cells from TLR4 deficient mice [33]. Overall,
TLR4 exerts a protective role with respect to smoke-
induced emphysema development. It is not still evident
whether the same mechanism is applied to human and
further study is necessary. TLR4 expression seemed asso-
ciated with emphysema severity which was reported to
be more correlated with airflow limitation (FEV1/FVC)
than COPD stage defined by FEV1 (% predicted) [36].
Several TLR4-dependent mechanisms are likely to be
involved in cigarette smoke-induced pulmonary inflam-
mation. Smoke may activate TLR4 signaling on pulmonary
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macrophages, which act as the first line of defense against
external threats [16,37]. Innate immunity mediated by
TLR4 also triggers the first-line host defense response to
Gram-negative bacterial infections and is crucial for initi-
ating subsequent T cell-mediated adaptive immune
responses [37]. TLR4 expression on the respiratory epithe-
lium allows for rapid activation of host defenses against
outside stimuli such as smoke and bacteria, resulting in
the induction of inflammatory mediators and antimicro-
bial peptides. The increased risk for bacterial infection in
patients with COPD may be caused by an inability to ef-
fectively clear bacteria and by misguided inflammatory
responses. Emphysema develops due to chronic inflamma-
tion and impaired matrix and cellular repair. Thus, an
impaired defense owing to TLR4 deficiency combined
with repeated inflammation may result in the develop-
ment of emphysema. However, it is unclear whether the
reduced TLR4 expression in patients with COPD is an
adaptive response to increased exposure to external
threats such as Gram-negative bacteria or smoke, as part
of the phenomenon of endotoxin tolerance.
Several limitations of this study should be noted. First,
the causal relationship between down-regulated TLR4
expression and emphysema is ambiguous. To make a
firm conclusion, smokers should be followed for several
decades after obtaining lung tissues or respiratory cells;
however, such studies are not practical and present eth-
ical issues. Similar experiment using other tissues or
blood-born cells could have clarified this issue more, but
we could not because they were not available. However,
our data showed that smoke-induced emphysema itself
did not affect TLR4 expression, providing more evidence
that down-regulated TLR4 expression results in emphy-
sema. Previous reports showing that TLR4 knockdown
induces spontaneous emphysema also support this idea
[17]. Second, TLR4 expression can be induced or
decreased by LPS stimulation [29,38]. Thus, TLR4 ex-
pression levels can vary with different clinical conditions
such as Gram-negative bacterial infections. In our study,
lung tissues were taken during elective lung resection,
when patients were clinically stable without evidence of
pulmonary infection or exacerbation. Third, we could
not find a causable gene that could explain the differen-
tial TLR4 expression. Although we examined several
single-nucleotide polymorphisms in the TLR4 gene, in-
cluding minor alleles with frequencies >5% in the HAP
map of Asians, no significant results were identified
(data not shown). Epigenetic factors may be associated
with the differential expression of TLR4. Fourth, func-
tional aspects by down-regulation of TLR4 expression,
such as cytokine secretion, could not be evaluated and
because of the retrospective nature of this study.Conclusion
In conclusion, down-regulated TLR4 expression in lung
was associated with emphysema and airflow limitation
in smokers. This report will broaden our understanding
of COPD pathogenesis, although further studies are
required to clarify a causal relationship between down-
regulated TLR4 expression and emphysema.
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